International Journal of Hematology

, Volume 109, Issue 5, pp 572–577 | Cite as

Light-chain plasma cell myeloma caused by 14q32/IGH translocation and loss of the other allele

  • Yuji Nishio
  • Hirotaka SakaiEmail author
  • Yusuke Saiki
  • Akiko Uchida
  • Yu Uemura
  • Manabu Matsunawa
  • Yasushi Isobe
  • Masayuki Kato
  • Naoto Tomita
  • Ikuo Miura
Original Article


Light-chain plasma cell myeloma (LC-PCM) is a PCM subtype in which only immunoglobulin light-chain is secreted. However, the absence of immunoglobulin heavy-chain (IGH) production in this condition has not been fully elucidated. To address this issue, we retrospectively analyzed patients at our center with LC-PCM and found a group who had only split signals of IGH gene derived from 14q32/IGH translocations by fluorescence in situ hybridization (FISH). Six patients were identified with only split signals of the IGH gene derived from 14q32/IGH translocations. Five of these patients were newly diagnosed, while one had IgG-λ PCM at presentation, which transformed to λ LC-PCM after treatment. The translocation partners were identified in four patients: two cases of (11;14)(q13;q32) and two cases of (4;14)(p16;q32). The development of LC-PCM appears to be explained by the application of allelic exclusion in these patients, such that 14q32/IGH translocation in one allele contributes to the pathogenesis of PCM and the subsequent loss of the other allele is responsible for the loss of IGH production. These findings suggest that a FISH pattern of IGH with “split and loss” may constitute a unique subgroup of LC-PCM.


Immunoglobulin heavy-chain Chromosomal translocation Class switch recombination Allelic exclusion Bence Jones protein 


Compliance with ethical standards

Conflict of interest

I.M. is a consultant for SRL, Inc.


  1. 1.
    Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.CrossRefGoogle Scholar
  2. 2.
    Chesi M, Bergsagel PL. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol. 2013;97:313–23.CrossRefGoogle Scholar
  3. 3.
    Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611–22.CrossRefGoogle Scholar
  4. 4.
    Mckenna RW, Kyle RA, Kuehl WN, Harris NL, Coupland RW, Fend F. Plasma cell neoplasm. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al, editors. WHO Classification of Tumors, Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC; 2017. pp. 241–58.Google Scholar
  5. 5.
    Bladé J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am. 1999;13:1259–72.CrossRefGoogle Scholar
  6. 6.
    Szczepański T, van’t Veer MB, Wolvers-Tettero IL, Langerak AW, van Dongen JJ. Molecular features responsible for the absence of immunoglobulin heavy chain protein synthesis in an IgH(–) subgroup of multiple myeloma. Blood. 2000;96:1087–93.Google Scholar
  7. 7.
    Magrangeas F, Cormier ML, Descamps G, Gouy N, Lodé L, Mellerin MP, et al. Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. Blood. 2004;103:3869–75.CrossRefGoogle Scholar
  8. 8.
    McGowan-Jordan J, Simons A, Schmid M. International system for human cytogenomic nomenclature 2016. Basel: Kargener; 2016.CrossRefGoogle Scholar
  9. 9.
    Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–54.CrossRefGoogle Scholar
  10. 10.
    Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.CrossRefGoogle Scholar
  11. 11.
    Greipp PR, Raymond NM, Kyle RA, O’Fallon WM. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood. 1985;65:305–10.Google Scholar
  12. 12.
    Burnet FM. A modification of Jerne’s theory of antibody production using the concept of clonal selection. CA Cancer J Clin. 1976;26:119–21.CrossRefGoogle Scholar
  13. 13.
    Pernis B, Chiappino G, Kelus AS, Gell PG. Cellular localization of immunoglobulins with different allotypic specificities in rabbit lymphoid tissues. J Exp Med. 1965;122:853–76.CrossRefGoogle Scholar
  14. 14.
    Vettermann C, Schlissel MS. Allelic exclusion of immunoglobulin genes: models and mechanisms. Immunol Rev. 2010;237:22–42.CrossRefGoogle Scholar
  15. 15.
    Drayson M, Begum G, Basu S, Makkuni S, Dunn J, Barth N, et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood. 2006;108:2013–9.CrossRefGoogle Scholar
  16. 16.
    Fujii R, Ishikawa H, Mahmoud MS, Asaoku H, Kawano MM. MPC-1CD49e immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol. 1999;105:131–40.CrossRefGoogle Scholar
  17. 17.
    Walker BA, Wardell CP, Johnson DC, Kaiser MF, Begum DB, Dahir NB, et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood. 2013;121:3413–9.CrossRefGoogle Scholar
  18. 18.
    Brioli A, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L, et al. Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood. 2014;123:3414–9.CrossRefGoogle Scholar
  19. 19.
    Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica. 2007;92:143–4.CrossRefGoogle Scholar
  20. 20.
    Kühnemund A, Liebisch P, Bauchmüller K, zur Hausen A, Veelken H, Wäsch R, et al. ‘Light-chain escape-multiple myeloma’-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol. 2009;135:477–84.CrossRefGoogle Scholar
  21. 21.
    Tamura H. Immunopathogenesis and immunotherapy of multiple myeloma. Int J Hematol. 2018;107:278–85.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  1. 1.Division of Hematology and Oncology, Department of Internal MedicineSt. Marianna University School of MedicineKawasakiJapan

Personalised recommendations